Table 1.
Demographic and Clinical Characteristics of Participants (n=25)
| Male, n (%) | 13 (52) |
| Black, n (%) | 13 (52) |
| Mean Age at Transplant, y ± SD | 43 ± 12 |
| Mean Age at FSGS Diagnosis, y ± SD | 33 ± 11 |
| Median Duration on Dialysis, y (IQR) | 2 (1 – 6) |
| Pre-Transplant Urine, n (%) | 16 (64) |
| Median Pre-Transplant Proteinuria, g/g (IQR) (n=8) | 2.3 (1.1 – 10.0) |
| Primary Pre-Transplant Diagnosis, n (%) | |
| FSGS | 21 (84) |
| Other* | 2 (8) |
| Unknown | 2 (8) |
| No. of Transplants at Time of FSGS Recurrence, n (%) | |
| 1 | 18 (72) |
| 2 | 4 (16) |
| 3 | 3 (12) |
| Living Donor, n (%) | 15 (60) |
| Related | 5 (33) |
| Unrelated | 10 (67) |
| ABO-Incompatible Transplant, n (%) | 5 (20) |
| Median Time to Treatment Post-transplant, days (IQR) | 39 (4 – 287) |
| Pre-Treatment Laboratory and Renal Pathology Data | |
| Mean Proteinuria, g/g ± SD (n=23) | 5.04 ± 3.6 |
| Median Serum Creatinine, mg/dL (IQR) | 2.2 (1.8 – 3.2) |
| Median eGFR, mL/min/1.73 m2 (IQR) | 31.8 (21.0 – 43.8) |
| Mean Foot Process Effacement, % ± SD (n=24) | 58 ± 34 |
| Median suPAR, pg/mL (IQR) (n=12)‡ | 5460 (4269 – 6172) |
| Mean CRP, mg/L ± SD (n=12) (Ref. range 0–20) | 9.8 ± 4.3 |
Abbreviations: y, years; SD, standard deviation; IQR, interquartile range; g, gram
†
Among individuals who had pre-transplant urination and had no urine quantification data
*
One patient with IgA nephropathy and the other with lupus nephritis.
‡
Excludes individuals who underwent ABO-incompatible renal transplantation